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Summary.-The effects of sodium pentobarbitone anaesthesia, the presence of a
tumour, and local hyperthermia to a tumour-bearing leg, on the pharmacokinetics of
MISO in the mouse are reported. Analysis of MISO and its metabolite Ro 05-9963
was by high-performance liquid chromatography. The plasma kinetics of MISO
were largely unaffected by any of these treatments, but hyperthermia substantially
reduced tumour concentrations of the drug.
The effects of tumour site and size on unheated-tumour drug concentrations were
also studied, and an increase in tumour size was shown to decrease tumour MISO
levels, but to different degrees according to whether implanted in the leg or flank.
Uniformity of MISO distribution throughout heated and unheated tumours was
examined, and levels were found to be constant within tumours. The presence of a
temperature detector in heated tumours did not affect their drug concentration.
THE HYPOXIC CELL RADIOSENSITIZER
misonidazole (1-(2-nitroimidazol-1-yl)-3-
methoxy propan-2-ol; Ro 07-0582 from
Roche Laboratories; NSC-261037; MISO),
which is currently undergoing clinical
trials, has been shown to exhibit selective
cytotoxicity to hypoxic cells (Mohindra &
Rauth, 1976; Brown, 1975; Sutherland
et al., 1976). It has been further demon-
strated that this cytotoxicity is enhanced
by hyperthermia both in vitro (Bleehen
et al., 1976; Stratford & Adams, 1977) and
in vivo in the mouse (Bleehen et al., 1977;
GAeorge et al., 1977). This in vivo work in
the mouse has involved anaesthetizing the
animal, usually with sodium pentobarbi-
tone. Recently there has been a growing
awareness that the side effects of anaes-
thesia can grossly affect the end-points of
some experiments, for instance Saffan
(the veterinary equivalent ofAlthesin) has
been reported to increase the growth delay
of a solid tumour treated with Melphalan
(Peacock & Stephens, 1978). Sodium pento-
barbitone itself has been reported to alter
the radiosensitivity of various tumours
and normal tissues, sometinmes rendering
them radioresistant (Sheldon et al., 1977;
Keizer & Van Putten, 1]976) and some-
times more radiosensitive (Hornsey et al.,
1977; Hendry, 1978). It has also been
reported to have no influence on radio-
sensitivity (Douglas & Fowler, 1976;
Paterson & Matthews, 1951). It is there-
fore necessary to check the effect of an
anaesthetic in any system where it has
been used, and the first part ofthe present
paper describes our investigations into the
effect of sodium pentobarbitone on the
pharmacokinetics of MISO.
The effect of variation in temperature
on drug pharmacokinetics had not been
widely studied when the subject was re-
viewed by Ballard in 1974, with the con-
clusion that both hyperthermia and hypo-
thermia may in some instances influence
the pharmacokinetic behaviour of a drug.
For example, the rate of binding of 32p
Thiotepa to perfused hind limbs of dogs
was shown to be higher at tissue tempera-D. J. HONESS ET AL.
tures of 37-2-38-90C than at 23-9-26410C
(Rochlin et al., 1961). More recently a
detailed study of Adriamycin in whole-
body hyperthermic (42 5°C) and control
rabbits (Mimnaugh et al., 1978) revealed
no difference in clearance rate of the
parent drug, but significantly higher con-
centrations ofAdriamycin and its metabo-
lites in the skeletal muscle and duodenum
of hyperthermic animals. In this paper we
report investigations into the effect of
local hyperthermia on the pharmaco-
kinetics of MISO by studying plasma and
tumour concentrations of MISO and its
0-demethylated metabolite, Ro 05-9963.
We also report on the influence of tumour
size and site on MISO and Ro 05-9963
concentrations, on the uniformity of dis-
tribution of MISO within tumours and on
the effect of mechanical disturbance by
the temperature probe detectors on MISO
concentrations in tumours.
EXPERIMENTAL
Animals
Adult BALB/c mice were obtained from
the breeding colony at NIMR (Mill Hill,
London) and were housed in plastic cages on
sawdust bedding. They were fed PRD nuts
(Labsure Animal Diets, Poole, Dorset) and
allowedc water ad lib. Mice weighed 20-25 g.
Turnours
The tumour used throughout this work is
the subline of the EMT6 tumour now desig-
nated EMT6/Ca/VJAC, and it has been
described in detail elsewhere (Twentyman &
Bleehen, 1975). The tumour is maintained in
alternating in vivo/in vitro passages, regu-
larly returning to frozen stock. Tumours were
implanted using cells harvested from the 2nd
to 5th in vitro passage after an in vivo passage.
An inoculum of 105 cells in 0-1 ml growth
medium was used. Leg tumours were pro-
duced by i.m. inoculation in the lower leg, and
flank tumours by inoculation intradermally
(i.d.) in the previously plucked skin of the
flank.
Tumour volumes
Leg tumours.-Volumes were calculated
after taking caliper measurements of 2
mutually perpendicular diameters at right
angles to the axis of the leg, taking the mean
of these and calculating the volume as for a
sphere, then subtracting the volume of
normal leg. This method was found to be
acceptable for tumours greater than 6-0 mm
in mean diameter. (Any tumour in which the
difference between- diameters exceeded 1 0
mm was discarded.) Leg tumours usually
reached a mean diameter ofabout 8-0 mm by
Days 7 or 8, and for "small" leg tumours the
mean diameters were restricted to 7-75-8-5
mm, that is, 90-170 mm3. "Large" leg
tumours were usually grown by Days 10-11
and the mean diameters were restricted to
10 0-11 25 mm, equivalent to a volume of
350-550 mm3. For "very large" leg tumours
the mean diameters were restricted to 12-0-
13-75 mm, i.e. 700-1100 mm3.
Flank tumours.-Volumes were calculated
by measuring 3 mutually perpendicular axes
of the usually ovoid tumour, and calculating
the volume according to the method of
Watson (1976). Tumours usually arrived at a
volume ofabout 100 mm3 by Day 9. "Small"
flank tumours were used in the volume range
60-140 mm3 and "large" ones in the range
350-550 mm3.
Drugs
Supplies of MISO and its 0-demethylated
metabolite Ro 05-9963 (1-(2-nitroimidazole-
l-yl)-2,3 propandiol) were provided by Roche
Laboratories (Welwyn Garden City, Herts).
MISO was routinely dissolved in Hanks'
balanced salt solution at 25 mg/ml for the
high dose (1.0 g/kg) and 2X5 mg/ml for the
low dose (100 mg/kg). The solutions were
injected i.p. such that a 25g mouse received
1.0 ml. MISO solutions were prepared daily
and protected from light.
Sodium pentobarbitone (sodium 5-ethyl-
5(1-methylbutyl)-barbiturate; Sagatal) was
obtained from May and Baker Ltd (Dagen-
ham, Essex) as a 60mg/ml solution anddiluted
1 in 10 in Hanks' before injection. 60 mg/kg
was the standard initial dose for animals not
also receiving MISO and 40 mg/kg for those
treated with MISO. This reduced dose is
adequate, because MISO increases the anaes-
thetic effect of Sagatal. Animals being heated
usually require at least one repeat dose of
about 15 mg/kg to maintain anaesthesia for
the full heating time of 60 min. When used,
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Sagatal was always administered 10 min
before the injection of MISO.
Heating
Leg tumours were heated by immersion in
a temperature-controlled circulating water-
bath (Grant Instruments, Barrington) with
the water temperature controlled to +0-10C.
The waterbath temperature was monitored
with a mercury thermometer calibrated
against a thermometer standardized by the
National Physical Laboratory. Mice were
supported in a specially designed jig with
only the tumour-bearing leg immersed.
Heating was started 10 min after injection of
Sagatal and immediately after injection of
MISO. In all experiments the duration of
heating was 60 min at a waterbath tempera-
ture of 44TC. This produced an intra-tumour
temperature of 430 +0 6°C for small leg
tumours. Temperature monitoring of the
tumours, performed in one set ofexperiments
only, was by means of a 27-gauge needle
thermistor probe in association with a direct
reading electric thermometer (Light Labora-
tories, Brighton). The needle was inserted into
the flank above water level and passed down
to the tumour s.c. in order to minimize errors
in temperature reading due to conduction
along the needle. The same apparatus fitted
with a special blunt temperature probe was
used to measure rectal temperatures.
Measurement ofplasma and tumour concentra-
tions of MISO and Ro 05-9963
At appropriate times after MISO injection,
mice were bled by cardiac puncture, using
diethyl ether anaesthesia where necessary.
Tumours were dissected out directly after
cardiac puncture. Blood and tumour samples
were put on ice immediately after collectioni.
Plasma was obtained by centrifugation
(2000 g for 10 min) of heparinized whole
blood, and stored at -20TC, as were tumour
samples. Plasma and tissue homogenate
(10% to 20% w/v in distilled water) were
analysed by reversed-phase high-performance
liquid chromatography (HPLC) as previously
described (Workman et al., 1978). This tech-
nique allows the specific assay ofMIS and the
0-demethylated metabolite, Ro 05-9963.
Estimation ofpharmacokinetic parameters
For up to 6 or 8 h after a dose of 1 0 g/kg of
MISO, the elimination of MISO from the
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plasma closely approximates to first-order
kinetics. The apparent elimination rate con-
stant (Kei) is given by the slope ofthe plot of
log MISO concentration against time, and
was estimated by the method ofleast squares
linear regression. The apparent half-life (t4)
is given by ln2/Kei. The area under the curve
(AUC) of a drug has been widely used as a
measure of tissue exposure. The AUCs of
plasma or tumour MISO and Ro 05-9963
concentrations were estimated by Simpson's
rule. When the AUC for both compounds is
converted from jg.h/ml to ,umol.h/ml the
AUCs can be summed to give the total nitro-
imidazole AUC.
RESULTS
Effect ofSagatal on MISOpharrmacokinetics
The dose of Sagatal used to anaes-
thetize mice also treated with 10 g/kg
MISO (e.g. in heating experiments) is 40
mg/kg. The effect of this dose on MISO
pharmacokinetics was investigated in non-
tumour-bearing mice. Fig. 1 shows the
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FIG. 1.-Effect of Sagatal on the pharmaco-
kinetics of high-dose MISO in normal, non-
tumour-bearing male mice. A A Plasma
MISO without Sagatal. 0 -0- Plasma
MISO with Sagatal. , Plasma Ro 05-9963
without Sagatal. C Plasma Ro 05-9963
with Sagatal. Representative 2 s.e. bars
are shown at Ih and 31i points for AIISO. 5
animals per group. Lines are fitted by
least squares regression.
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TABLE I.-Effects of Sagatal on the pharmacokinetics of MISO in normal and pheno-
barbitone-pretreated male mice after a 10 g/kg dose of MISO
AUCo-8ht
,umol h/ml
Apparent
Sagatal MISO t
Pretreatment anaesthesia (h) Mil
A None None 2-36 15-
(2-02-2 83)
40 mg/kg 2-12 17-
(1.90-2 40)
B Phenobarbitone None 1-09 8-
5 days at 100 mg/kg (0-99-1-24)
40 mg/kg 1-08 7-
(0-91-1-36)
95% confidence limits in parentheses (5 animals per time point).
t No significance tests possible for AUC.
time courses of plasma MISO and Ro MISO pL
05-9963 after 1-0 g/kg MISO in control and ured at
Sagatal-treated male mice, and Table I injection,
shows the t, values and AUCs (Part A). are showi
There is no significant difference between is no obsE
the ti values (P> 0 1). Similar results of the tui
were obtained in repeat experiments and
also in female animals. 100
Previous studies have shown that the ti
can be shortened by phenobarbitone pre- E
treatment with 100 mg/kg daily for 5 days g
before MISO treatment (Workman, 1979). z
Part B in Table I shows that Sagatal has 0
no effect in the induced mice. We also <
demonstrated that Sagatal had no effect on
tumour concentrations of MISO and Ro z
05-9963. For example, MISO concentra- 8
tions in small flank tumours 40 min after 1
injection were 359 + 23 (2 x s.e.) pg/g in 2
control mice and 385 + 18 ,ug/g in mice 2
treated with Sagatal (n= 5 in both cases; a
P>0*1).
Effect of the presence of a tumour on MISO s
pharmacokinetics
Previous studies have shown that solid
tumours may inhibit the metabolism of
drugs (Sladek et al., 1978). In view ofthis,
a series of experiments was carried out on
male mice with and without small leg
tumours, using low-dose MISO (100 mg/ FIG. 2.-
kg); the low dose was used since any small tumoul
difference due to the presence of a tumour beareti
would probably be more apparent at the tumou
low dose. Tumours were not heated, but tumotu non-tua
mice were anaesthetized with Sagatal. square,
Total 2-
Ro 05-9963 nitroimidazole
1*75 17*55
SO
*80
04 1-92
*17 2-17
90 2-09
18-96
10*34
9.99
asma concentrations were meas-
30min intervals for 3 h after
, and data from one experiment
n in Fig. 2, illustrating that there
ervable effect due to the presence
mour. The apparent t. values are
A A
* 0
A
1 2 3 4
TIME h
-Effect of the presence of a small leg
ir on low-dose MISO pharmaco-
-s. C-- -- Plasma MISO in tumour
s. A-A Plasma MISO in non-
r bearers. * Plasma Ro 05-9963 in
r bearers. * Plasma Ro 05-9963 in
imour bearers. Lines fitted by least-
,s regression.
A
I
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TABLE II.-Apparent MISO ti after a
100 mng/kg dose of MISO to anaesthetized
male mice, with and without "small" leg
tumours
ti (h)
Without
Expt tumour
A 0 73
(0 51-1.28)
B 0-61
(0.56-0 69)
C 0-60
(0.48-0.79)
t (h)
With
tumour
0-67
(0 55-0 88)
0-67
(0 62-0 73)
0-69
(0.58-0-86)
95% confidence limits in parentheses. 3 animals
per group.
given in Table II, experiment B being the
one illustrated in Fig. 2. There is no sig-
nificant difference between ti values,
P> 0*1 in all cases. The t, values quoted
here for the low dose (100 mg/kg) are
shorter than those shown in Table I for
1.0 g/kg. This is due to the dose-depend-
ence of MISO pharmacokinetics (Work-
man, in preparation). Comparison between
high-dose experiments also showed that
there were no differences due to the
presence ofa tumour.
Effect of local heat on plasma and tumour
levels of MISO and Ro 05-9963
The effect ofheat onplasma and tumour
levels of MISO and its metabolite was
investigated in male animals with small
leg tumours (see experimental section)
which were heated for 1 h at a waterbath
temperature of 44TC. As part ofthis study
we also investigated the effects of MISO
with and without local heating on the core
temperature of anaesthetized mice.
High dose studies
1*0 g/kg MISO was injected i.p. into
anaesthetized animals at the start of
heating. Unheated animals were also
anaesthetized. In all three experiments
plasma MISO levels were similar in locally
heated and control animals for up to 6 h.
Later plasma levels were rather higher in
the heated animals, so that plasma MISO
t. values tended to be somewhat higher in
locally heated animals. However, this
difference was only significant (P < 0 02) in
one experiment for which the data are
illustrated in Fig. 3 and pertinent phar-
macokinetic parameters are summarized
in Table III. In the other experiments the
t, values for locally heated and control
animals respectively were 2-44 and 1-97 h
in one, and 3 09 and 2-44 h in the other. In
neither experiment was the difference sig-
nificant (P> 0 1). In all 3 experiments the
plasma MISO AUCs were similar for
locally heated and control animals, and
Ro 05-9963 levels were not affected.
All experiments showed a lower tumour
MISO and Ro 05-9963 level in heated than
unheated tumours, the difference being
greater at the earlier times (upto 3 h) (Fig.
3). This produced a lower AUC for heated
tumours, an effect which is described in
greater detail below.
Low-dose studies
In view of the difference in MISO
pharmacokinetics at high and low doses,
the effect of local hyperthermia was
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FIG. 3.-Effect of local hyperthermia of the
tumour-bearinglegonhigh-doseMISOlevels
in plasma and tumour. O-Q Unheated
plasma MISO. 0- - - Heated plasma
MISO C Unheated tumourMISO.* Heated
tumour MISO. 3 mice per point. Lines
fitted by least-squares regression.
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TABLE III. Effect of 1 h local heat to the tumour onplasma and tumnour concentrations of
MISO and Ro 05-9933 after a 1-0 g/kg dose of MISO
Control
Plasma
AUCo-8 h
fimoibh/mi
Apparent Total 2-
MISO tt (h) MIIS() Ro 05-9963 nitroimidazole
1-83 18-95 1-82 20-77
(1-67-2-02)
Heat 2-70
(2-40-3-08)
Heat/
Control AUCo-sh
21-27 1-71 22-98
1-12
Tumour
AUCo-8h
Pmol.h/ml
Total 2-
MISO Ro 05-9963 nitroimidazole
7-65 0-14 7-79
5-73 0-11 5-84
0-75
95%O confidence limits in parentheses. 3 animals per time point.
examined at the low dose of MISO. The
experiment was repeated exactly as above
but using a 100mg/kg dose of MISO and
measuring plasma and tumour levels of
MISO and Ro 05-9963 at 0-5, 1, 2, 3 and
4 h only after MISO administration, as
100'
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Fic. 4.-Effect of local hypertliermia of the
tumour-bearing leg on low-dose MISO
levels in plasma. 0-0 Unheated plasma
MISO. 0- - - Heated plasma MISO.
V Unheated plasma Ro 0-9963. V Heated
plasma Ro 95-9963 Lines are fitted by least
squares regression.
levels fall below the detectable limit at
later times. The time courses of both
measured drugs are shown in Fig. 4 and
are seen to be very similar in heated and
control animals. The apparent MISO ti
for heated and control animals are 1-02 h
(0.84-1-28 h) and 0-95 h (0.77-1-24 h)
respectively, and there is no significant
difference between these values (P > 0-1).
It was found that tumour levels of MISO
and Ro 05-9963 were undetectable in all
cases.
Effect of local heating on core temperature
Measurements of rectal temperature, as
a measure of core temperature, have been
made on unanaesthetized and MISO-
treated anaesthetized heated and un-
heated mice at an ambient temperature of
26-5°C. Unanaesthetized, untreated mice
have a rectal temperature of about
38-38-5°C, whereas the temperature of
anaesthetized (40 mg/kg Sagatal) mice
treated with 1-0 g/kg MISO drops by an
average of 5TC during the first hour and
then steadily rises during the next 9 h so
that it has returned to normal by 10 h
after drug administration. Although a
dose of 60 mg/kg Sagatal (which produces
a similar level of anaesthesia to 40 mg/kg
Sagatal in conjunction with 1-0 g/kg
MISO-see "Drugs" section) also causes a
temperature drop of about 5TC, this effect
is relatively short-lived, the minimum
temperature being recorded 40 min after
the drug is given, and by 2 h after the
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temperature is within 0 5°C of that of
untreated controls. The effect of 1.0 g/kg
MISO on unanaesthetized animals is
almost the same as on anaesthetized ones,
the temperature dropping by an average
of 4°C in the first hour. The time scale of
recovery is similar to that for anaes-
thetized mice: normal by 10 h after treat-
ment following a steady rise from 2 h after
treatment. The temperatures of locally
heated, anaesthetized mice also treated
with 1.0 g/kg MISO show more variation
between animals, and they rise to a maxi-
mum after about 30 min of heating (from
39*5 to 40 5°C) when further anaesthetic
is required and the temperature drops to
between 38-5 and 39 5°C. It then rises
gradually or remains approximately
steady for the remaining heating time.
Thus the core temperatures of heated
and unheated mice after treatment with
10 g/kg MISO are very different during
the hour of heating, differences of up to
7°C being quite likely. After heating, the
temperatures of heated animals drop, so
that the discrepancy between core tem-
peratures of heated and unheated mice
diminishes.
Effect of heat, size and site on high dose
MISO levels in tumours
In these experiments MISO levels were
ineasured in tumour and plasma at 2
selected times only, 1 and 3 h after in-
jection of 1-0 g/kg of MISO. The effect of
heat for 1 h after the injection ofMISO in
large and small tumours was examined,
and also the effect of tumour size in both
leg and flank, using 3 sizes of leg tumour
and 2 offlank tumour. Small leg and flank
tumours were of similar volume, as were
large tumours in both sites (see "Experi-
mental" section for sizes used). No flank
tumours were heated, but all mice were
anaesthetized with Sagatal. All experi-
ments demonstrated the same trend and
the results of one are summarized in
Table IV. TheMISO tumour: plasma ratios
are seen to be consistently lower in heated
than in control tumours (P<0-01 for 1 h
data and P < 0-001 for 3h data). Also, in
both flanks and legs, large tumours have a
lower ratio than small ones (P < 0 001 for
both times) but no further decrease is seen
in very large leg tumours. The tumour:
plasma ratios in unheated small leg and
flank tumours were similar, as might be
expected, but the same increase in size
decreased the tumour: plasma ratio more
in leg tumours than in flank tumours
(P < 0-001 for lh data and P < 0-01 for 3h
data). Similarly, the effect of heat on
large leg tumours appeared to be pro-
portionately greater than on small leg
tumours, but this was significant at 3 h
only (P > 0.2 for lh data and P < 0-01 for
3h data).
The probabilities quoted above were
calculated by carrying out an analysis of
variance on log tumour: plasma ratios,
considering firstly the effects of heat and
size and their interaction, and then the
effects of site and size and their inter-
action. Results of this analysis are given
in Table V to illustrate the relative sig-
nificance ofthe effects. The effect ofsize is
the most significant, having the greatest
F ratio.
Uniformity of MISO distribution in heated
and unheated tumours
It has been shown that cell survival is
higher in the centre than the periphery of
heated tumours with 1.0 g/kg MISO
(Bleehen et al., 1977). Although it seemed
likely that a higher temperature at the
periphery accounted for the lower sur-
vival there, it was possible that a non-
uniform distribution of MISO throughout
the tumour might have contributed to
this phenomenon. Experiments were
therefore carried out using male mice with
leg tumours given 1.0 g/kg MISO and
either heated for 1 h in a 44°C waterbath
or left at room temperature. All mice were
anaesthetized with Sagatal. Tumours
were excised 1 h after injection with
MISO, i.e. immediately after heating
when appropriate, and carefully dissected
into peripheral and central areas which
were assayed separately. Data from one
experiment are shown in Table VI. They
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TABLE IV.-Effect of heat, size and site on tumour/plasma ratios of MISOfor a 1 0g/kg
dose ofMISO
Control
Small leg
tumours
(90-170 mm3)
Large leg
tumours
(350-550mm3)
Very large
leg tumours
(700-1100mm3)
Small flank
tumours
(60-140mm3)
Large flank
tumours
(350-550 mm3)
Time Tumour Plasma
(h) (Yg1g) (Kg/ml)
1 326-5 621-6
+ 44-3 +31-6
(n= 10)
3 139-1 281-7
+28-7 +28-3
(n=10)
1 98-9 739.4
+ 43-3 + 65-2
(n= 10)
3 84-3 456-6
+21-3 + 58-6
(n= 10)
1 118-4 924-6
+ 37-8 + 77-8
(n=9)
3 125-5 508-8
+33-2 +45-7
(n= 8)
1 387-0 665-7
+ 57-8 + 73-3
(n= 10)
3 219-9 432-1
+46-3 +50 5
(n= 10)
1 265-1 874-1
+69-1 +50-2
(n=8)
3 179-9 511-5
+ 59-5 + 110-5
(n=8)
Tumour
Plasma
(%)
52-5
49.4
13-4
18-5
Heat
A .-
Tumour
Tumour Plasma Plasma
5g1g) (60g9ml) (%)
252-1 609-8 41*3
+42-8
138-7
+ 39-9
47-6
+ 15-0
28-8
+ 13-8
12-8
+22-1
(n= 10)
338-8
+ 35-3
(n=8)
815-0
I ++74-5
(n= 11)
437-5
+43-4
(n=9)
nd
24-7
40-9
5'8
6*5
nd
58-1
50 9
30 3
35*2
nd
nd
nd
nd
Figures are mean + 2 s.e. of n determinations.
nd=not determined.
TABLE V.-Results ofanalysis ofvariance on log tumour/plasma ratiosfor lh and 3h data
from Table IV
lh data
Effect F ratio P
Heat
Size
Heat x size
Site
Size
Site x size
8-2 < 0 01
138-9 < 0 001
1.51 > 0-2
18-4 <0.001
81-0 < 0 001
13-5 < 0 001
show that there is no significant difference
(P > 0 1) in MISO concentrations between
the centres and peripheries of tumours
having had the same treatment, i.e. either
heated or controls. However, the differ-
ence reported above between heated and
unheated tumours is again seen. There is
a significant difference in tumour concen-
3h data
F ratio P
22-9 <0.001
930 <0001
10-2 <0.01
13-0 < 0.001
64-6 < 0 001
11-7 <0.01
trations, for both peripheral and central
portions, between heated and unheated
tumours (P < 001).
Effect ofthe presence of a temperatureprobe
on tumour levels of MISO
Having previously reported that the
presence ofa temperature probe can affect
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TABLE VI.-CoMnparison of MISO and Ro 05-9963 levels (pug/g) in central andperipheral
areas of leg tumours, heated and unheated, for a IP0 g/kg dose of MISO
Control (n= 10)
MISO Ro 05-9963
729
203
694
160
24 6
5 8
16 3
4.7
Heat (n=9)
MISO Ro 05-9963
354
91
317
120
16 9
2-7
14 7
4-1
the survival of tumours treated with
MISO and heat (Honess et al., 1978) we
investigated the possibility that the bleed-
ing caused by the probe could cause
higher MISO levels in monitored than un-
monitored tumours. Experiments were
carried out on male mice bearing small leg
tumours heated for 1 h after administra-
tion of 1-0 g/kg MISO. They had been
anaesthetized with Sagatal 10 min before
receiving MISO. Tumours were excised
immediately after heating, and the results
indicated no significant difference between
monitored and unmonitored tumours
(P > 0.1); hence the extra cell killing in the
presence ofthe probe cannot be attributed
to higher MISO levels.
DISCUSSION
In this paper we have shown that
sodium pentobarbitone anaesthesia does
not alter the plasma kinetics of MISO in
normal mice. We have also shown that the
presence of a tumour does not affect the
plasma MISO levels. Neither the anaes-
thetic nor the tumour had a significant
effect on the half-life or AUC. Also the
oxidative demethylation to the Ro 05-
9963 metabolite was unchanged. We
therefore proceeded to investigate the
effect oflocal hyperthermia on plasma and
tumour kinetics of MISO, being as certain
as possible that no differences that might
be observed could be attributed to an
anaesthetic artefact, anaesthesia being
unavoidable in our current method of
tumour heating.
Local hyperthermia was found to have
very little effect on the plasma pharmaco-
kinetics of MISO. There was, however, a
tendency for the plasma MISO t- in locally
heated animals to be rather longer at the
high dose (1.0 g/kg) ofMISO, but this was
not significant in 2/3 experiments, nor at
the low dose (100 mg/kg). The increase in
t, was due to higher plasma levels at the
later times (8-12 h), when no more than
20% of the peak drug concentration re-
mained. As a result, the MISO AUC was
not affected. Previous reports have sug-
gested that the toxicity ofMISO is related
to the AUC (Dische et al., 1977; Workman,
1979). Our finding that hyperthermia does
not affect the plasma AUC of MISO is
interesting in view oftheincreasedtoxicity
of the drug by this treatment (Overgaard,
1979; unpublished results). This suggests
that other factors may also be involved in
the toxicity. Our finding that locally
applied hyperthermia, which also caused a
systemic temperature rise of between
2 and 3°C, has very little effect on the
pharmacokinetics of MISO is essentially
similar to that of Mimnaugh (1978) on
Adriamycin in rabbits. In that study the
core temperature of hyperthermic animals
was 2 5°C higher than that of controls.
In contrast to the finding that local
heating had little effect on systemic
MISO pharmacokinetics, this treatment
was found to reduce the MISO tumour
levels, differences of up to 70% being
found in the early samples. Other studies
on tissue uptake of drug at raised tem-
peratures deal with normzal tissues, e.g.
dog leg (Rochlin et al., 1961) and rabbit
skeletal muscle and duodenum (Mim-
naugh, 1978) and they both demonstrate
a higher level in the heated normal tissue.
It seems unlikely that the reduction in
MISO concentration could be due to in-
Periphery
Centre
mean
2 x s.e.
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creasedoxidativemetabolisminthetumour
(which is on average 2°C hotter than the
maximum core temperature) because cor-
respondingly higher Ro 05-9963 levels
might be expected, yet these were found
to be unchanged. However, we cannot rule
out the possibility that more rapid
metabolism by other routes may be
responsible. It is also possible that the
decreased MISO concentrations in heated
tumours are lower due to a reduction in
the blood supply. This might be caused by
heat-induced oedema constricting the
blood vessels in the leg; oedema is brought
about within 30 min of immersion in a
44°C water bath. Alternatively, it may be
caused by a reduction in blood flow to the
heated tumour, associated with a drop in
blood pressure caused by sodium pento-
barbitone. We did show that in the ab-
sence of heat sodium pentobarbitone did
not affect tumour MISO concentration,
but were unable to compare heated
tumours with andwithout the anaesthetic.
Johnson et at. (1976) have measured blood
pressure and tumour blood flow at differ-
ent temperatures in CBA and WHT mice
bearing leg tumours under sodium pento-
barbitone anaesthesia. Observations were
made on blood flow at 20 and 39°C.
Whereas at 20°C the anaesthetic caused a
slight decrease in blood flow followed by
recovery, at 39°C it caused falls ofbetween
5 and 20%. The authors speculate that
the effect ofsodium pentobarbitone on the
blood flow at hyperthermic temperatures
suggests that the lowered blood pressure
decreases total tumour perfusion. If this
is indeed the case in this work, then we
have not contrived to avoid all anaesthetic
artefacts.
Bleehenetal. (1977) haveshownthat cell
survival, as measured by in vitro plating
assay, is lower at the periphery of heated
MISO-treated tumours than at the centre.
We have shown that there is no difference
between the MISO concentrations at the
periphery and centre of such tumours.
Thus the possibility that lower drug con-
centrations in hotter parts of the tumour
can lower the overall concentration in
heated tumours is eliminated. It appears
that the difference is for the tumour as a
whole, as would be indicated by the im-
pedance of blood flow, by whatever
mechanism.
The finding that the tumour drug con-
centration can be reduced by heating is
importantfordrugstheinvivocytotoxicity
of which is enhanced by hyperthermia,
such as MISO itself, cyclophosphamide
(unpublished observations) and bleomycin
(Marmor, 1979). In these cases, the poten-
tial effect must exceed the observed effect,
since the heated tumours have received
less drug than the controls. This must be
considered in evaluating the exploitability
ofsuch an enhancement.
The observation that tumour size and
implantation site in unheated tumours
influence the MISO concentration in those
tumours is also significant. It is perhaps to
be expected that larger tumours would
have lower total levels of drug, because
part of their volume is composed of a
necrotic centrewithnointactbloodsupply,
which will receive drug only by diffusion.
Donelli et al. (1977) have shown in intra-
muscular Lewis lung tumours, for a
variety of cytotoxic agents, that drug is
mainly to be found in the viable part, with
very little in the necrotic parts of the
tumour. None the less it is surprising that
the same increase in tumour size has more
effect on the drug concentration in leg
tumours than in flank tumours. This may
be due to differences in geometry and
hence the relative sizes of necrotic centres
in leg and flank tumours with similar
calculated volumes. The demonstration
that, irrespective of site, large tumours
have lower concentrations of drug than
small ones may be of importance with
regard to reports of investigations with
other drugs where small tumours have
shown greater sensitivity, estimated by
growth delay, than large ones. This
phenomenon has been reported for the
response of the Lewis lung tumour to
cyclophosphamide (Steel & Adams, 1975)
and for the response of the P815X2
mastocytoma and the EMT6 tumour to
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BCNU (Schenken, 1976; Twentyman,
1978). Perhaps the effect is partly a re-
flection of the actual tumour drug dose as
well as the usually accepted explanation
in terms of proliferative state.
The demonstration that MISO levels
are the same in monitored and un-
monitored tumours shows that the greater
cell killing in heated monitored tumours
treated with MISO (Honess et al., 1978)
cannot be attributed to higher drug levels
due to intra-tumoural haemorrhage. It
may therefore be caused by better tem-
perature equilibration of the monitored
tumours due to conduction along the
metal probe within the tumour, or by
direct mechanical damage.
The main conclusions from this work
are that the pharmacokinetics of MISO
are unaffected by sodium pentobarbitone
anaesthesia and very slightly affected by
hyperthermia at a 44TC water bath tem-
perature for 1 h. However, tumour levels
of MISO are reduced. Also tumour levels
of MISO in unheated tumours vary
according to size and site. It seems un-
likely that this phenomenon should be
confined to MISO and, ifit were shown to
occur for other drugs also, it would at
least partially account for some of the
reports of variation in tumour chemo-
sensitivity with size.
We thank Ms Jane Donaldson for expert technical
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and Dr C. Smithen of Roche Products Limited for
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